These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26192258)

  • 1. Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?
    Satasivam P; Poon BY; Ehdaie B; Vickers AJ; Eastham JA
    J Urol; 2016 Jan; 195(1):74-9. PubMed ID: 26192258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.
    Vargas HA; Akin O; Afaq A; Goldman D; Zheng J; Moskowitz CS; Shukla-Dave A; Eastham J; Scardino P; Hricak H
    J Urol; 2012 Nov; 188(5):1732-8. PubMed ID: 23017866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance.
    Dai C; Ganesan V; Nyame YA; Almassi N; Greene DJ; Hettel D; Magi-Galluzzi C; Gong M; Jones JS; Stephenson AJ; Berglund RK; Klein EA
    Urology; 2019 Aug; 130():106-112. PubMed ID: 31071349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-institutional evaluation of active surveillance for low risk prostate cancer.
    Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B
    J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance.
    Anderson CB; Sternberg IA; Karen-Paz G; Kim PH; Sjoberg D; Vargas HA; Touijer K; Eastham JA; Ehdaie B
    J Urol; 2015 Dec; 194(6):1607-11. PubMed ID: 26119671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.
    Komisarenko M; Wong LM; Richard PO; Timilshina N; Toi A; Evans A; Zlotta A; Kulkarni G; Hamilton R; Fleshner N; Finelli A
    J Urol; 2016 Feb; 195(2):307-12. PubMed ID: 26417646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
    Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
    J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
    Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
    Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of perineural invasion and race in men considering active surveillance.
    Cohn JA; Dangle PP; Wang CE; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    BJU Int; 2014 Jul; 114(1):75-80. PubMed ID: 24106869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer.
    Ginsburg KB; Arcot R; Qi J; Linsell SM; Kaye DR; George AK; Cher ML;
    J Urol; 2019 May; 201(5):923-928. PubMed ID: 30694939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
    Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
    J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.